If you've ever experienced a migraine, you know how debilitating they can be.
As many as 16-18 million people in the U.S. suffer from migraines, a form of a headache that causes intense throbbing throughout your head while also inducing nausea, sensitivity to light, and occasional vomiting.
Symptoms can also include seeing wavy/squiggly lines or spots of light, mood changes and dips in your appetite.
Fortunately, there's a new drug on the market to help treat migraines which involves a brain chemical called CGRP.
How can this drug stop the pain before it starts?
Richard Lipton, MD, joins Dr. Leigh to discuss migraines and the new drug that promises to stop migraines before they actually start.
New Migraine Drug: Stops Pain Before it Starts
How does the new migraine drug (CGRP) work?
Additional Info
- Segment Number: 1
- Audio File: ER_101/1526er5a.mp3
- Featured Speaker: Richard Lipton, MD
- Organization: Albert Einstein College of Medicine
-
Guest Bio:
Richard B. Lipton, M.D., is the Edwin S. Lowe Professor and Vice-Chair of Neurology, Professor of Epidemiology and Population Health and Professor of Psychiatry and Behavioral Sciences at Einstein.
He also is Director of the Montefiore Headache Center. After graduating from the University of Chicago Pritzker School of Medicine, he did both a neurology residency and a fellowship in Clinical Neurophysiology and Epilepsy at Einstein.
He did a second fellowship in Neuro-epidemiology at the Columbia University. A UCNS-certified headache clinician, he is also a clinical trialist and epidemiologist. He is Past President of the American Headache Society and currently serves on the AHS Board. He is also Chair of the AHS's Chronic Migraine Education Program (CMEP).
He has written over 600 articles in peer reviewed journals and 10 books, including two editions of Wolff's Headache, as well as Headache in Clinical Practice and Migraine and Other Headaches.
His research interests include the epidemiology and burden of episodic migraine as well as risk factors and prevention of chronic migraine. He has developed several measures widely used in clinical practice and research, including ID-Migraine, ID-Chronic Migraine, the Migraine Disability Assessment Scale (MIDAS), the Migraine Treatment Optimization Questionnaire (mTOQ), as well as the Allodynia Symptom Checklist (ASC).
His work has also examined migraine genetics and biomarkers, migraine's comorbidities as well as health-related quality of life and health economics. He has conducted numerous clinical trials and lead national and international clinical trials. He is on the Editorial Boards of several journals, including Neurology.
Dr. Lipton is a three-time winner of the Wolff Award and recipient of the Enrico Greppi Award, all for excellence in headache research. He was recently identified by Thompson Scientific as the most frequently referenced author of scientific publications on migraine in the world. - Length (mins): 10
- Waiver Received: No
- Host: Leigh Vinocur, MD
Published in
The Dr. Leigh Vinocur Show
Tagged under